Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

What condition was this medication prescribed to treat?

Medical problems since taking Enbrel:

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Enbrel Side Effects Lawsuits | Side Effects: Blood Reactions, Hematological Disorders, Autoimmune Disease, Systemic Lupus Erythematosus (SLE)

Amgen & Wyeth - IMPORTANT DRUG WARNING 3/14/08

Amgen & Wyeth - Enbrel DRUG WARNING for Subcutaneous Injection

Enbrel Side Effects May Be Linked To Autoimmune Disease Lawsuits

Enbrel | Lawsuits, Lawyers | Side Effects: Blood Reactions, Hematological Disorders, Autoimmune Disease, Systemic Lupus Erythematosus (SLE)

The FDA approved Enbrel (Generic: Etanercept), which is used to treat Rheumatoid Arthritis, on June 6, 2000. Enbrel is a popular drug used by over 70,000 Rheumatoid Arthritis patients in the United States. On October 17, 2000, Immunex Corp. the manufacturer of Enbrel stated that the drug might cause serious blood reactions and stimulate nervous system disorders. Reports of 10 such incidences, half of which were fatal, prompted this action by Immunex.

The central nervous system disorders that Enbrel patients encountered include Multiple Sclerosis, Myelitis and Optic Neuritis, Pancytopeni and Aplastic Anemia. In a public statement in October 2000, Immunex commented that, In the majority of these cases, there was a close temporal relationship between the start of treatment with Enbrel and the occurrence of hematological disorders (range two weeks to five months). Since the clinical experience with Etanercept is still limited as this product has only recently been marketed, onset after this period cannot be ruled out.

In Europe, where the drug has been available since February 2000, the European Medicines Evaluation Agency also urged doctors to exercise caution when prescribing the medication. They stressed the need to inform patients about the possible signs and symptoms of blood disorders and infections.

On February 15, 2002 researchers in Chicago reported that four (4) women with Rheumatoid Arthritis developed symptoms of the autoimmune disease Systemic Lupus Erythematosus (SLE) after taking the Enbrel. The patients developed symptoms including face reddening and body rash while taking the drug, but the symptoms disappeared when the drug was halted, according to a research letter in the February 16, 2000 issue of The Lancet

Legal Help For Victims Affected By Enbrel

If you or a loved one took Enbrel and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or call us at 1-800-YOURLAWYER (1-800-968-7529).


EnbrelRSS Feed

Legionella, Listeria Infections Added to Black Box Warning for TNFa Blockers

Sep 8, 2011 | Parker Waichman LLP
Patients treated with Remicade, Enbrel, Humira, Cimzia and Simponi are at an increased risk of developing Listeria or Legionella infections.  Such drugs, known as Tumor Necrosis Factor-alpha (TNFa) blockers, are immunosuppressive drugs, and it was already known that such medications increased a patient’s risk of serious infections.In a Drug Safety Communication issued yesterday, the U.S. Food & Drug Administration (FDA) announced that information regarding Legionella and Listeria...

FDA Releases More Humira, Enbrel, Remicade Info

Sep 1, 2009 | Parker Waichman LLP
Federal regulators have released  more information regarding cancers associated with drugs like Humira, Enbrel, and Remicade.  Last month, the Food & Drug Administration  (FDA) had mandated that the Black Box  Warnings on these drugs - known as TNF blockers -   highlight their possible  association with lymphoma and other cancers in children and teens.In a  supplementary "Question and Answer" document released yesterday, the FDA provided more...

Group Calls For Study Of Arthritis Drugs

Jul 1, 2009 | Parker Waichman LLP
Arthritis and other autoimmune medications have made recent headlines over a variety of issues including links to serious opportunistic fungal infections and cancer. Now, as part of President Barack Obama’s health care overhaul, a review of arthritis medications manufactured by Wyeth, Abbott Laboratories, and Johnson & Johnson (J&J) might warrant some additional scrutiny, reports Recently, we reported that federal regulators ordered the makers of Humira, Cimzia,...

Simponi Carries Risk of Possibly Fatal Fungal Infections

May 29, 2009 | Parker Waichman LLP
Simponi, a new rheumatoid arthritis drug, can cause severe and potentially fatal fungal infections, according to a new warning released yesterday by the Food & Drug Administration (FDA). Because of this risk, the agency said that when  making a decision to use Simponi, doctors must balance the potential benefits with the potential risks of therapy based upon a patient’s individual need.Simponi is one of a class of drugs known as TNF-alpha blockers.  Such medications work by...

Humira, Cimzia, Enbrel and Remicade to Bear Stronger Infection Warnings

Sep 4, 2008 | Parker Waichman LLP
Federal regulators have ordered the makers of Humira, Cimzia, Enbrel, and Remicade to strengthen the existing warnings about opportunistic fungal infections linked to the drugs.  At least 45 people are known to have died from such infections.  The Food & Drug Administration (FDA) ordered the new labeling under authority it was granted with the passage of the Food and Drug Administration Amendments Act of 2007.Humira, Cimzia, Enbrel and Remicade are known as tumor necrosis factor...

More Enbrel News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo